Clinical trial

Margetuximab Expanded Access Program

NCT03133988

StatusAPPROVED_FOR_MARKETING

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2025-02-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Breast Cancerunresolved

HER2-positive Carcinomaunresolved

Interventions

MargetuximabBIOLOGICAL

Sponsors & collaborators

TerSera Therapeutics LLClead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03133988 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.